XML 27 R17.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Information
 9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Segment Information Segment Information
Lexicon operates as a single reportable segment, primarily focusing on the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Substantially all of the Company’s revenues have been derived from drug discovery alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, technology licenses, subscriptions to its databases, product sales, government grants and contracts and compound library sales, as well as from commercial sales of its approved drug product.

The chief operating decision maker (“CODM”) is the Company’s chief executive officer (“CEO”). The CEO manages and allocates resources on a total company basis by assessing the overall level of resources available and how to best deploy these resources across research and development projects in line with the Company’s long-term company-wide strategic goals.

The CEO evaluates single-segment consolidated financial information against budget for purposes of making operating decisions, planning and forecasting for future periods, and deciding the level of investment in the Company’s various operating activities and other capital allocation activities. The CODM assesses financial performance based on consolidated net income (loss) (as reported on the consolidated statement of comprehensive income (loss)). The CEO also uses consolidated cash and cash equivalents and short-term investments (which can be found on our Consolidated Balance Sheets) as a measure of segment assets for allocating resources.

Summary of segment net income (loss), including segment expenses were as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2025202420252024
(in thousands)(in thousands)
Revenues:
Net product revenue$1,008 $1,741 $3,592 $4,451 
Licensing revenue13,154 — 40,698 — 
Royalties and other revenue20 9 20 76 
Total revenues14,182 1,750 44,310 4,527 
Operating expenses:
Cost of sales10 71 73 268 
Research and development16,799 24,314 44,535 53,056 
Sales and marketing1,149 27,822 5,057 79,484 
General and administrative4,841 7,067 19,133 20,541 
Other segment expense (1) (2)
3,570 6,169 9,643 15,558 
Total operating expenses26,369 65,443 78,441 168,907 
Loss from operations(12,187)(63,693)(34,131)(164,380)
Interest and other expense(2,155)(4,562)(6,308)(11,721)
Interest income and other1,573 3,444 5,628 9,464 
Net loss$(12,769)$(64,811)$(34,811)$(166,637)

(1) For the three and nine months ended September 30, 2025 and 2024, other segment expense includes stock compensation of (i) $1.8 million, $1.5 million, $5.0 million, and $4.7 million, respectively, related to research and development personnel and (ii) $1.6 million, $0.8 million, $4.6 million, and $4.7 million, respectively, related to general and administrative personnel. For the three and nine months ended September 30, 2024, other segment expense primarily includes, among other items, stock compensation of $0.6 million and $2.6 million, respectively, related to sales and marketing personnel.
(2) For the three and nine months ended September 30, 2025, other segment expense includes, among other items, severance costs of $0.1 million and $0.2 million, respectively, related to research and development personnel. For the three and nine months ended September 30, 2024, other segment expense includes, among other items, severance costs of (i) $2.5 million and $2.7 million, respectively, related to sales and marketing personnel and (ii) $0.9 million and $0.9 million, respectively, related to general and administrative personnel.